glp 1 alcohol reduction GLP-1 Anti-Obesity Rx and and Substance Use Disorders Frontiers | The therapeutic potential

[11] GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications primarily licensed in the UK for the treatment of type 2 diabetes and, more recently, for weight management in specific patient groups

MDL 3094, created in February 2024 in the Eastern District of Pennsylvania, consolidates gastrointestinal injury claims

Over about six months, they reported that the injectable group lost a little more on average, around 5.26 kg (about 11.5 lbs) versus 3.64 kg (roughly 8 lbs) for the oral group

In conclusion, it seems that GLP-1/exendin-4 acts in the VMH and LH, modulating the activation status of AMPK and S6K1 in response to glucose fluctuations, helping to improve pathophysiological states such as obesity and insulin resistance

[DOI] [PubMed] [Google Scholar] 763.Skov J., Pedersen M., Holst J.J., Madsen B., Goetze J.P., Rittig S